1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Roche Holding AG

Roche Holding AG

ROG.TO
Roche Holding AGCA flagToronto Stock Exchange
27.30
CAD
-0.40
- -
18.81BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
2.74
2.78
2.81
2.95
3.11
3.31
3.57
3.39
3.68
4.09
3.76
3.9
3.96
Basic EPS, GAAP
0.66
0.55
0.52
0.56
0.5
0.61
0.78
0.83
0.82
0.77
0.72
0.52
0.81
Free Cash Flow per Basic Share
0.76
0.74
0.65
0.58
0.81
0.88
1.02
0.69
0.96
0.82
0.71
0.94
0.82
Dividend per Share
0.37
0.39
0.41
0.41
0.42
0.42
0.43
0.45
0.45
0.46
0.47
0.48
0.48
Book Value per Share
22.72
23.05
24.62
28.07
30.97
32.35
38.27
42.6
30.6
35.03
36.77
39.94
42.49
Tangible Book Value per Share
9.66
-3.7
-4.65
0.68
9.36
10.92
13.67
17.67
1.95
9.37
6.39
8.28
8.78
Basic Weighted Avg Shares
17,044
17,064
17,104
17,124
17,144
17,165
17,205
17,185
17,084
16,079
16,059
16,019
15,999
Sales/Revenue/Turnover
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
Operating Margin (%)
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
Depreciation Expense
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
Net Income, GAAP
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
Effective Tax Rate (%)
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
Profit Margin (%)
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
Working Capital
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
LT Debt
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
Total Equity
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
Return on Invested Capital (%)
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
Return on Capital (%)
29.52
23.01
20.28
21.27
18.59
22.09
26.96
26.23
22.89
19.89
18.78
12.39
18.18
Return on Common Equity (%)
66.04
48
43.7
42.66
34.29
38.84
44.72
41.38
45.8
47.34
40.13
27.1
39.29

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
62,395
2025
- -
- -
- -
- -
63,356
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.52
2025
- -
- -
- -
- -
0.81
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.48
2025
- -
- -
- -
- -
0.48
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Thomas Schinecker
Full Time Employees
112,774
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Grenzacherstrasse 124 Basel BS Switzerland 4070
IPO Date
Oct 23, 2025
Website
roche.com
Similar Companies
Bayer Aktiengesellschaft (BAYN.SG)
Otsuka Holdings Co., Ltd. (4578.T)
Biogen Inc. (0R1B.L)
Organon & Co. (OGN)
Orion Oyj (ORNBV.HE)
Novartis AG (NVSEF)
Business
Roche Holding AG is a global healthcare company that researches, develops, manufactures and commercializes pharmaceuticals and diagnostics, with additional digital solutions designed to support precision healthcare; the company was founded in 1896 and is headquartered in Basel, Switzerland. Its Pharma division includes medicines across oncology, hematology, immunology, ophthalmology, neurology, infectious diseases and cardiovascular, renal and metabolic diseases, while its Diagnostics division offers in vitro diagnostics, clinical chemistry, immunodiagnostics, molecular diagnostics, tissue diagnostics, digital pathology, laboratory automation and related services; Roche also operates through Genentech in the United States and holds a majority stake in Chugai Pharmaceutical in Japan. Roche continues to expand its partnering and acquisition strategy, reporting more than 240 partnerships across Pharma, 75 new diagnostics agreements in 2025 and 24 diagnostics acquisitions since 2014, alongside a global partnership with Nurix Therapeutics to advance the BTK degrader bexobrutideg. In 2025 and 2026, Roche completed the acquisitions of Poseida Therapeutics, SAGA Dx and 89bio, agreed to acquire PathAI to strengthen AI-driven digital pathology and diagnostics, and entered into a collaboration and license agreement with Zealand Pharma to co-develop and co-commercialize petrelintide for people who are overweight or have obesity. The company has also emphasized a more selective, partnership-led innovation model, with management highlighting productivity gains in its pipeline and continued investment in digital pathology, companion diagnostics and AI-enabled laboratory workflows.